Highlights
- •The SF-MPQ-2 assesses the major symptoms of both neuropathic and nonneuropathic pain.
- •It has been used in previous studies of diverse chronic pain disorders, including clinical trials.
- •The SF-MPQ-2 was found to have excellent validity in acute low back and radicular leg pain.
- •Existing data indicate that the SF-MPQ-2 is a valid measure of neuropathic and nonneuropathic pain.
Abstract
The Short-form McGill Pain Questionnaire (SF-MPQ-2) assesses the major symptoms of
both neuropathic and nonneuropathic pain and can be used in studies of epidemiology,
natural history, pathophysiologic mechanisms, and treatment response. Previous research
has demonstrated its reliability, validity, and responsiveness in diverse samples
of patients with chronic pain. However, the SF-MPQ-2 has not been evaluated for use
in patients with acute pain. Data were examined from a double-blind, randomized clinical
trial of immediate-release tapentadol versus immediate-release oxycodone in patients
with acute low back and associated radicular leg pain (N = 666). Analyses of internal
consistency, convergent validity, and confirmatory factor structure were conducted
using baseline data, and analyses of responsiveness were conducted using baseline
and endpoint data. The SF-MPQ-2 total score and its 4 subscale scores (continuous
pain, intermittent pain, predominantly neuropathic pain, and affective descriptors)
generally showed good psychometric properties and 1) were internally consistent, 2)
displayed good convergent validity, 3) fit the a priori factor structure, and 4) were
highly responsive to analgesic treatment. These data extend previous evidence of the
reliability, validity, and responsiveness of the SF-MPQ-2 in patients with chronic
pain to those with acute low back and associated radicular leg pain.
Perspective
Considered together with the results of other recent studies, the data suggest that
the SF-MPQ-2 can provide a valid, responsive, and efficient assessment of both neuropathic
and nonneuropathic pain qualities for clinical trials and other clinical research
examining patients with various acute and chronic pain conditions.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Reliability, validity, and sensitivity measures of expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2) in Iranian patients with neuropathic and non-neuropathic pain.Pain Med. 2012; 13: 1631-1638
- Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome?.Eur J Pain. 2011; 15: 441-443
- The LANSS Pain Scale: The Leeds assessment of neuropathic pain symptoms and signs.Pain. 2001; 92: 147-157
- Using screening tools to identify neuropathic pain.Pain. 2007; 127: 199-203
- Tapentadol IR versus oxycodone IR for treatment of acute low back pain.Pain Physician. 2013; 16: E237-E246
- The validity of the Hospital Anxiety and Depression Scale: An updated literature review.J Psychosom Res. 2002; 52: 69-77
- On the definitions and physiology of back pain, referred pain, and radicular pain.Pain. 2009; 147: 17-19
- Development and validation of the Neuropathic Pain Symptom Inventory.Pain. 2004; 108: 248-257
- Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).Pain. 2005; 114: 29-36
- Pain assessment: Global use of the Brief Pain Inventory.Ann Acad Med Singapore. 1994; 23: 129-138
- An eight-week yoga intervention is associated with improvements in pain, psychological functioning and mindfulness, and changes in cortisol levels in women with fibromyalgia.J Pain Res. 2011; 4: 189-201
- Reliability is necessary but far from sufficient: How might the validity of pain ratings be improved?.Clin J Pain. 2014 Nov 3; ([Epub ahead of print]. http://dx.doi.org/10.1097/AJP.0000000000000175)
- Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial.Neurology. 2003; 60: 1274-1283
- Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.Pain. 2005; 113: 9-19
- Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2).Pain. 2009; 144: 35-42
- Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.J Pain. 2008; 9: 105-121
- The evaluation of neuropathic components in low back pain.Curr Pain Headache Rep. 2009; 13: 185-190
- PainDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain.Curr Med Res Opin. 2006; 22: 1911-1920
- Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: A prospective observational pilot study (MIPORT).Curr Med Res Opin. 2006; 22: 529-537
- Pseudoradicular and radicular low-back pain—a disease continuum rather than different entities? Answers from quantitative sensory testing.Pain. 2008; 135: 65-74
- Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale.Neurology. 1997; 48: 332-338
- Acceptance of pain: A study in patients with advanced cancer.Pain. 2009; 143: 147-154
- Validation of the Short-Form McGill Pain Questionnaire-2 in younger and older people with cancer pain.J Pain. 2014; 15: 756-770
- Morphine, gabapentin, or their combination for neuropathic pain.N Engl J Med. 2005; 352: 1324-1334
- Item analysis of cancer patient responses to the Multidimensional Affect and Pain Survey demonstrates high inter-item consistency and discriminability and determines the content of a short form.J Pain. 2005; 6: 67-74
- NeuPSIG guidelines on neuropathic pain assessment.Pain. 2011; 152: 14-27
- The Pain Quality Assessment Scale: Assessment of pain quality in carpal tunnel syndrome.J Pain. 2006; 7: 823-832
- Cognitive testing and revision of the Pain Quality Assessment Scale.Clin J Pain. 2013; 29: 400-410
- The McGill Pain Questionnaire: Development, psychometric properties, and usefulness of the long form, short form, and short form-2.in: Turk D.C. Melzack R. Handbook of Pain Assessment. 3rd ed. Guilford Press, New York, NY2011: 45-66
- Principles and Practice of Structural Equation Modeling.2nd ed. Guilford Press, New York, NY2005
- Validation of the Multidimensional Affect and Pain Survey (MAPS).J Pain. 2006; 7: 161-169
- Development of a neuropathic pain questionnaire.Clin J Pain. 2003; 19: 306-314
- Evaluation of the psychometric properties of the Revised Short-form McGill Questionnaire.J Pain. 2012; 13: 1250-1257
- Power analysis and determination of sample size for covariance structure modeling.Psychol Methods. 1996; 1: 130-149
- Towards physiologically based treatment of patients with neuropathic pain.Pain. 1990; 42: 131-133
- The McGill Pain Questionnaire: Major properties and scoring methods.Pain. 1975; 1: 277-299
- The short-form McGill Pain Questionnaire.Pain. 1987; 30: 191-197
- The McGill Pain Questionnaire: From description to measurement.Anesthesiology. 2005; 103: 199-202
- What is localized neuropathic pain? A first proposal to characterize and define a widely used term.Pain Manag. 2012; 2: 71-77
- Responsiveness of the Oswestry Disability Index and the Roland Morris Disability Questionnaire in Italian subjects with sub-acute and chronic low back pain.Eur Spine J. 2012; 21: 122-129
- The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer.Br J Psychiatry. 1991; 148: 255-259
- Research Design and Statistical Analysis.2nd ed. Lawrence Erlbaum Associates, Mahwah, NJ2003
- The Short-form McGill Pain Questionnaire 2 to evaluate persistent pain and surgery related symptoms in healthy women undergoing a planned cesarean delivery.Reg Anesth Pain Med. 2014; 39: 478-486
- Development and testing of a neuropathic pain screening questionnaire: ID Pain.Curr Med Res Opin. 2006; 22: 1555-1565
- Exploratory and confirmatory factor analysis of the PROMIS pain quality item bank.Qual Life Res. 2014; 23: 245-255
- The Roland-Morris Disability Questionnaire and the Oswestry Disability Questionnaire.Spine. 2000; 25: 3115-3124
- A study of the natural history of back pain, Part I: Development of a reliable and sensitive measure of disability in low back pain.Spine. 1983; 8: 141-144
- Scientific approach to the assessment and management of activity-related spinal disorders, a monograph for clinicians: Report of the Quebec Task Force on Spinal Disorders.Spine. 1987; 12: S1-S59
- Validation of a revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2) for IBS patients.Govaresh. 2012; 17: 91-97
- Making sense of Cronbach's alpha.Int J Med Educ. 2011; 2: 53-55
- On assessing responsiveness of health-related quality of life instruments: Guidelines for instrument evaluation.Qual Life Res. 2003; 12: 349-362
- Neuropathic pain: Redefinition and a grading system for clinical and research purposes.Neurology. 2008; 70: 1630-1635
- Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.Pain. 2006; 125: 208-215
- The dimensions of pain quality: Factor analysis of the Pain Quality Assessment Scale.Clin J Pain. 2008; 24: 550-555
- Towards a mechanism-based classification of pain?.Pain. 1998; 77: 227-229
- The Hospital Anxiety and Depression Scale.Acta Psychiatr Scand. 1983; 67: 361-370
Article info
Publication history
Published online: January 29, 2015
Accepted:
January 15,
2015
Received in revised form:
December 23,
2014
Received:
August 6,
2013
Footnotes
Support for the clinical trial from which the data analyzed in this article were derived was provided by Janssen Scientific Affairs, which also provided a research grant to Analgesic Solutions to support data analyses and publication preparation.
Permission to use the SF-MPQ-2 can be obtained from the Mapi Research Trust, Lyon, France (e-mail: [email protected]; website: www.proqolid.com). Dr. Ronald Melzack and the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration share licensing fees from for-profit organizations using the SF-MPQ-2 in their research. R.H.D. has received in the past 12 months a research grant from the U.S. Food and Drug Administration (grant no. U01FD004187) and compensation for activities involving clinical trial research methods from Acetylon, Astellas, AstraZeneca, Avanir, Axsome, Biogen, Centrexion, Charleston, Chromocell, Daiichi-Sankyo, Eli Lilly, Hydra, Johnson & Johnson, Lpath, Maxwell Biotech, Metys, Olatec, Phosphagenics, QRx, Relmada, Salix, Sorrento, Spinifex, Teva, and Virobay. D.C.T. has received in the past 12 months a research grant from the U.S. Food and Drug Administration (grant no. U01FD004187) and consulting fees or honoraria in the past year from Lilly, Mallincrodt, Orexo, Ortho-McNeil Janssen, Pfizer, and Xdynia. J.J.T. was a full-time employee of Analgesic Solutions at the time the study was conducted and the first draft of the manuscript was prepared. D.M.B., M.K., and C.B. are full-time employees of Johnson & Johnson. N.P.K. is the owner of Analgesic Solutions.
Identification
Copyright
© 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.
